MSD unveils plans for $1.3bn central London research centre

MSD has lifted the lid on plans to build a $1.3 billion research centre in central London.
The London Discovery Research Centre, as the site is to be named, has a tentative opening date of 2025 and will be based opposite King’s Cross station.
Construction is due to commence in late 2021, contingent on a successful sign-off from the London borough of Camden. In order to free up the proposed 25,000-square-metre space, the existing group of buildings at the site will first need to be demolished.
The facility will reportedly focus on early-stage research, predominantly for age-related conditions, generating 120 research and technician roles and 800 positions in total.
MSD first announced the project in 2017 but has suffered delays due to difficulties around finalising a site in the UK capital for the centre to be based. Due to a five-year neuroscience partnership that MSD has struck with the Francis Crick Institute, the company had been aiming to base its new facility at the nearby life sciences hub in North London.
Matt Fellows
- Login or register to post comments
- Printer-friendly version
Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches
Related content
- NICE rejects Merck Serono’s Bavencio for urothelial cancer
- Merck kidney and uterus cancer treatments granted priority review by FDA
- Merck cease development of $425 million COVID-19 treatment
- Positive five-year Keytruda survival data revealed at ESMO in metastatic, PD-L1+ non-small cell lung cancer
- MSD partners up with Seattle Genetics in two oncology development deals potentially worth over $4bn